Urothelial Cancer

GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.

Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.

Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.

Timothy N. Clinton, MD, and Stephanie A. Berg, DO, discuss gender differences in bladder cancer during Bladder Cancer Awareness Month.

Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.

Drs Armstrong and Tawagi provide a comprehensive review of metastatic urothelial carcinoma management.

Timothy N. Clinton, MD, discusses initiatives to improve outcomes for female patients with bladder cancer.

Timothy N. Clinton, MD, discusses biologic and anatomical differences underlying sex and gender disparities in bladder cancer incidence.

Timothy N. Clinton, MD, discusses differences between genders in terms of bladder cancer presentation.

Drs Armstrong and Tawagi review localized bladder cancer diagnosis and management, including initial histology and evolving treatment paradigms.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A response to neoadjuvant chemotherapy was associated with long-term survival benefits in high-risk UTUC.

Sac-TMT produced durable responses with a manageable safety profile in pretreated advanced/metastatic urothelial carcinoma.

The FDA has granted priority review to the sBLAs for pembrolizumab and subcutaneous pembrolizumab plus enfortumab vedotin in cisplatin-eligible MIBC.

During an Onclive Peer Exchange, panelists examined the utility of circulating tumor DNA in bladder cancer and other genitourinary malignancies.

Jeffrey Zhong, MD, discusses the effect of upfront enfortumab vedotin/pembrolizumab dose reduction on treatment efficacy in advanced urothelial carcinoma.

Erda-iDRS was safe and produced early efficacy signals in FGFR-altered NMIBC.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, colorectal cancer, breast cancer, chronic myeloid leukemia, and multiple myeloma.

The FDA cleared relacorilant plus nab-paclitaxel in ovarian cancer, the primary end point of the SENTRY trial in myelofibrosis was met, and more.

The NCCN has added the IBCG risk stratification model for intermediate-risk NMIBC to its Clinical Practice Guidelines in Oncology for bladder cancer.

Drs Armstrong and Tawagi spotlight the most practice-informing data to come out of the 2026 Genitourinary Cancers Symposium.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Nadofaragene firadenovec has been added to the NCCN guidelines in BCG-unresponsive papillary NMIBC without CIS.